REGENERON PHARMACEUTICALS (1REGN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1REGN - US75886F1075 - Common Stock
628.2 EUR
+15.6 (+2.55%)
We assign a fundamental rating of 7 out of 10 to 1REGN. 1REGN was compared to 82 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1REGN a very profitable company, without any liquidiy or solvency issues. 1REGN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
1REGN had positive earnings in the past year.
In the past year 1REGN had a positive cash flow from operations.
1REGN had positive earnings in each of the past 5 years.
1REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1REGN has a Return On Assets of 11.40%. This is amongst the best in the industry. 1REGN outperforms 86.75% of its industry peers.
Looking at the Return On Equity, with a value of 14.79%, 1REGN belongs to the top of the industry, outperforming 85.54% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 8.25%, 1REGN belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
1REGN had an Average Return On Invested Capital over the past 3 years of 11.81%. This is in line with the industry average of 12.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.25% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.81%
ROIC(5y)17.22%
1.3 Margins
The Profit Margin of 1REGN (32.13%) is better than 86.75% of its industry peers.
1REGN's Profit Margin has improved in the last couple of years.
1REGN has a better Operating Margin (27.61%) than 84.34% of its industry peers.
1REGN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 86.28%, 1REGN is in the better half of the industry, outperforming 77.11% of the companies in the same industry.
In the last couple of years the Gross Margin of 1REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1REGN is creating some value.
1REGN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1REGN has less shares outstanding
The debt/assets ratio for 1REGN has been reduced compared to a year ago.
2.2 Solvency
1REGN has an Altman-Z score of 7.34. This indicates that 1REGN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.34, 1REGN belongs to the best of the industry, outperforming 85.54% of the companies in the same industry.
The Debt to FCF ratio of 1REGN is 0.70, which is an excellent value as it means it would take 1REGN, only 0.70 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.70, 1REGN belongs to the top of the industry, outperforming 90.36% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that 1REGN is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.09, 1REGN is doing good in the industry, outperforming 61.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.34 |
ROIC/WACC0.97
WACC8.51%
2.3 Liquidity
A Current Ratio of 4.06 indicates that 1REGN has no problem at all paying its short term obligations.
1REGN has a better Current ratio (4.06) than 78.31% of its industry peers.
1REGN has a Quick Ratio of 3.51. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 1REGN (3.51) is better than 68.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
1REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
Measured over the past years, 1REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
Looking at the last year, 1REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
Measured over the past years, 1REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
The Earnings Per Share is expected to grow by 6.38% on average over the next years.
Based on estimates for the next years, 1REGN will show a small growth in Revenue. The Revenue will grow by 5.63% on average per year.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.35, the valuation of 1REGN can be described as correct.
83.13% of the companies in the same industry are more expensive than 1REGN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.59. 1REGN is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 15.97 indicates a correct valuation of 1REGN.
Based on the Price/Forward Earnings ratio, 1REGN is valued cheaper than 90.36% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.03, 1REGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.35 | ||
| Fwd PE | 15.97 |
4.2 Price Multiples
77.11% of the companies in the same industry are more expensive than 1REGN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1REGN indicates a rather cheap valuation: 1REGN is cheaper than 85.54% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.92 | ||
| EV/EBITDA | 14.72 |
4.3 Compensation for Growth
1REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.25
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
1REGN has a yearly dividend return of 0.47%, which is pretty low.
Compared to an average industry Dividend Yield of 0.80, 1REGN pays a better dividend. On top of this 1REGN pays more dividend than 91.57% of the companies listed in the same industry.
With a Dividend Yield of 0.47, 1REGN pays less dividend than the S&P500 average, which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
BIT:1REGN (12/11/2025, 7:00:00 PM)
628.2
+15.6 (+2.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.98%
Inst Owner ChangeN/A
Ins Owners1.91%
Ins Owner ChangeN/A
Market Cap66.02B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80
Price Target665.79 (5.98%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)5.15%
PT rev (3m)4.3%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)15.5%
EPS NY rev (1m)2.68%
EPS NY rev (3m)21.62%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)4.29%
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)6.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.35 | ||
| Fwd PE | 15.97 | ||
| P/S | 5.43 | ||
| P/FCF | 19.92 | ||
| P/OCF | 15.25 | ||
| P/B | 2.5 | ||
| P/tB | 2.61 | ||
| EV/EBITDA | 14.72 |
EPS(TTM)38.43
EY6.12%
EPS(NY)39.33
Fwd EY6.26%
FCF(TTM)31.53
FCFY5.02%
OCF(TTM)41.2
OCFY6.56%
SpS115.75
BVpS251.5
TBVpS240.28
PEG (NY)N/A
PEG (5Y)1.25
Graham Number466.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.25% | ||
| ROICexc | 10.81% | ||
| ROICexgc | 11.38% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.81%
ROIC(5y)17.22%
ROICexc(3y)17.18%
ROICexc(5y)23.98%
ROICexgc(3y)18.1%
ROICexgc(5y)24.53%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.34 |
F-Score5
WACC8.51%
ROIC/WACC0.97
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-4.04%
EBIT Next 3Y6.12%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / 1REGN.MI FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI.
What is the valuation status for 1REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (1REGN.MI). This can be considered as Fairly Valued.
What is the profitability of 1REGN stock?
REGENERON PHARMACEUTICALS (1REGN.MI) has a profitability rating of 8 / 10.
What is the earnings growth outlook for REGENERON PHARMACEUTICALS?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (1REGN.MI) is expected to decline by -3.81% in the next year.